From Spreadsheets to Secure Pipelines: Modernizing Biotech File Transfers Without Slowing the Science Down

The overlooked key in biotech is how data actually moves from one system, partner or team to another. MFT can be a game-changer.

In biotech, speed isn’t optional. It’s existential. Whether advancing a clinical trial, sequencing genomes or collaborating with research partners, timelines are tight and the stakes are high. But behind many of these cutting-edge efforts lies a surprisingly fragile foundation: how data actually moves from one system, partner or team to another.

Spreadsheets shared over email. Files dropped into shared folders. Legacy FTP servers quietly running in the background.

These methods persist not because they’re effective, but because they’re familiar, fast to set up and “good enough” in the moment. And then an auditor asks for a complete transfer log and your team spends days piecing one together from emails and shared drive histories. Or an FTP upload silently fails overnight, and no one notices until a submission deadline is missed. Or a clinical trial dataset gets misdirected to the wrong contract research organization (CRO) contact and you have no system log to tell you when it happened or who had access.

As data volumes surge and regulatory scrutiny intensifies, these ad-hoc file transfer workflows are becoming one of the most overlooked risks in biotech organizations. The challenge is clear: how do you modernize file transfers—making them more secure, compliance-ready and scalable—without slowing down the science?

The Hidden Costs of ‘Good Enough’ File Transfers

Biotech organizations operate in a uniquely complex data environment. Clinical trial data, genomic sequences (which can range from gigabytes to terabytes per sample depending on the sequencing method), imaging files, patient records and partner datasets all move across organizational boundaries daily. These files are not only large and numerous, they are often sensitive, regulated and business-critical.

Yet in many organizations, the infrastructure supporting this data movement hasn’t kept pace. Email handles smaller datasets. FTP servers manage bulk transfers. Shared folders become informal collaboration hubs. Each tool serves a narrow purpose, but together they create a fragmented ecosystem with limited visibility and inconsistent controls.

The risks start small: a missed file, a delayed upload, a version mismatch. Over time they compound: inconsistent processes, lack of accountability and potential security gaps. Most critically, these workflows create blind spots. Leadership and IT teams often lack a centralized view of what data is being transferred, where it’s going and whether it’s adequately protected.

File Transfer as a Compliance Risk

For biotech companies, file transfer isn’t just an operational concern; it’s a regulatory one.

Data exchanged during clinical trials frequently includes protected health information (PHI), bringing it under the scope of HIPAA. Civil monetary penalties for willful violations can reach into the millions per year, and OCR closed 22 enforcement actions with financial penalties in 2024 alone—one of its busiest years on record. International collaborations add GDPR requirements, where data residency, consent and auditability are legally mandated. Proprietary compounds, genomic insights and trial designs add a layer of IP sensitivity on top.

Ad-hoc transfer methods often struggle to address all of these demands simultaneously:

• Email attachments can be forwarded or downloaded without any access controls or audit trail.
• Legacy FTP implementations commonly lack strong encryption and detailed logging, leaving transfers unprotected and unauditable.
• Shared folders depend on manual permission management, which drifts over time and creates unauthorized access risks.

When auditors ask, “Who accessed this file?” or "Can you prove this data was transferred securely?” many organizations are forced into manual reconstruction, piecing together logs from multiple systems or relying on incomplete records. That’s a compliance gap that becomes visible at the worst possible moment.

The Scale Problem Is Already Here

Biotech isn’t just generating more data. It’s generating it faster and sharing it with more stakeholders than ever. CROs, diagnostic labs, manufacturing partners, payers and regulatory bodies all require timely, accurate data exchanges. Each relationship introduces new workflows, formats and expectations.

What starts as a handful of file transfer processes scales quickly into dozens or hundreds of recurring exchanges. Many are still managed manually: someone exports a dataset, uploads it, sends a notification and waits for confirmation. This doesn’t scale and it doesn’t need to, because there’s a better approach.

What Modern File Transfer Actually Looks Like

Modernizing file transfers doesn’t mean slowing down workflows or adding friction. The goal is the opposite: data moves faster, more securely and with complete visibility. This is where a managed file transfer (MFT) approach delivers.

A modern MFT platform, like Progress MOVEit, centralizes and standardizes how files move across the organization and its ecosystem. Instead of relying on scattered tools and manual handoffs, all transfers are managed through a unified system built for security, automation and auditability.

Security controls are built in, not improvised.

Files are encrypted in transit and at rest. Access controls are enforced consistently, reducing the risk of misconfigured folders or misdirected emails exposing sensitive data.

Automation reduces reliance on manual intervention.

Routine transfers—sending trial data to a CRO, receiving lab results, distributing updated datasets to multiple partners—can be scheduled, triggered by events or integrated directly into existing systems like LIMS or cloud analytics platforms.

Visibility becomes an asset.

Transfers can be logged, tracked and made auditable. IT and compliance teams can see what’s happening in real time and generate audit-ready reports on demand—not after a days-long reconstruction effort.

Protecting PHI and IP by Design

In biotech, data is the foundation of both innovation and trust. A modern file transfer strategy is designed to help protect both PHI and intellectual property through layered controls: encryption, secure protocols and role-based access that’s enforced by the system rather than dependent on individual users making the right call every time.

For organizations navigating HIPAA and GDPR requirements, this shift is critical. Audit trails provide exportable records that support compliance efforts. Data handling becomes repeatable and defensible. And accidental exposure through misdirected emails or misconfigured shared folders is structurally prevented, not just discouraged.

Faster Collaboration Across Your Ecosystem

Biotech innovation depends on a network of partners working together across geographies and systems. A modern file transfer approach makes those collaborations more seamless by replacing one-off solutions with a more standardized, security-focused framework that new collaborators can be onboarded into quickly.

In practice, this means a clinical trial sponsor can automatically distribute updated datasets to multiple CROs while receiving structured outputs in return. Labs upload results directly into secure pipelines, triggering downstream processes without manual intervention. Payers and regulators access required data through controlled, auditable channels.

Modernizing Without Disrupting Ongoing Work

The most common concern from biotech leaders: Will improving infrastructure slow down ongoing research? The short answer is no, if you approach it incrementally.

The most effective transitions start by identifying high-risk or high-volume workflows—clinical data exchanges, partner integrations—and migrating those first. MOVEit is designed to integrate with existing systems, from LIMS to cloud storage and analytics platforms, so organizations can enhance their data movement capabilities without overhauling their entire tech stack. The result is a more resilient foundation that supports innovation rather than competing with it.

Stop Rebuilding Audit Trails. Start Preventing the Gaps.

If your team has ever spent days reconstructing transfer logs before a regulatory review or discovered a failed file transfer only after a missed deadline, the problem isn’t effort, it’s infrastructure.

MOVEit software gives biotech organizations the tools to secure sensitive data, automate critical workflows and maintain a centralized, near-real-time audit trail across file transfer activity, without disrupting the pace of research.

Request a demo and see how MOVEit software can replace your fragmented transfer workflows with a single, auditable system designed to support biotech compliance requirements.